Evidence map›Paper›PMID 29293555›Full record

ArticlePloS one2018

MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines.

Cecilia M Lopez, Peter Y Yu, Xiaoli Zhang, Ayse Selen Yilmaz, Cheryl A London, Joelle M Fenger

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Possible Role of IL-6R/STAT3/MiRNA-34a Feedback Loop in Osteosarcoma.Asian Pacific journal of cancer prevention : APJCP · 2023
    Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. A miR-34a-guided, tRNACell death discovery · 2022
    Article
  12. Article
  13. Review
  14. Article
  15. Molecular Mechanisms of Canine Osteosarcoma Metastasis.International journal of molecular sciences · 2021
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Epigenetic Mechanisms in Canine Cancer.Frontiers in oncology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Cecilia M LopezDepartment of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, United States of America.
Peter Y YuMedical Student Research Program, The Ohio State University College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States of America.
Xiaoli ZhangCenter for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio, United States of America.
Ayse Selen YilmazCenter for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio, United States of America.
Cheryl A LondonDepartment of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, United States of America.
Joelle M FengerDepartment of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, United States of America.ORCID 0000-0003-1407-8856
The Ohio State University · USThe Ohio State University Wexner Medical Center · USTufts University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Jennifer A. Woyach · 1985 to 2026
$132.3M
The Ohio State University Center for clinical and Translational ScienceUL1TR001070 · NCATS · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2013 to 2017
$22.6M
Dissecting the role of miR-9 in normal and malignant mast cell biologyK01OD019923 · OD · OHIO STATE UNIVERSITY · PI FENGER, JOELLE M · 2015 to 2019
$654k
NCATS NIH HHS UL1 TR001070NCI NIH HHS P30 CA016058NIH HHS K01 OD019923NIH HHS P03CA016058NIH HHS UL1TR001070
6 · The paper itself

Abstract

backgroundOsteosarcoma (OSA) is the most common bone tumor in children and dogs; however, no substantial improvement in clinical outcome has occurred in either species over the past 30 years. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and play a fundamental role in cancer. The purpose of this study was to investigate the potential contribution of miR-34a loss to the biology of canine OSA, a well-established spontaneous model of the human disease. METHODOLOGY AND PRINCIPAL

findingsRT-qPCR demonstrated that miR-34a expression levels were significantly reduced in primary canine OSA tumors and canine OSA cell lines as compared to normal canine osteoblasts. In canine OSA cell lines stably transduced with empty vector or pre-miR-34a lentiviral constructs, overexpression of miR-34a inhibited cellular invasion and migration but had no effect on cell proliferation or cell cycle distribution. Transcriptional profiling of canine OSA8 cells possessing enforced miR-34a expression demonstrated dysregulation of numerous genes, including significant down-regulation of multiple putative targets of miR-34a. Moreover, gene ontology analysis of down-regulated miR-34a target genes showed enrichment of several biological processes related to cell invasion and motility. Lastly, we validated changes in miR-34a putative target gene expression, including decreased expression of KLF4, SEM3A, and VEGFA transcripts in canine OSA cells overexpressing miR-34a and identified KLF4 and VEGFA as direct target genes of miR-34a. Concordant with these data, primary canine OSA tumor tissues demonstrated increased expression levels of putative miR-34a target genes.

conclusionsThese data demonstrate that miR-34a contributes to invasion and migration in canine OSA cells and suggest that loss of miR-34a may promote a pattern of gene expression contributing to the metastatic phenotype in canine OSA.

Indexed as

AnimalsBone NeoplasmsCell Line, TumorDog DiseasesDogsKruppel-Like Factor 4Kruppel-Like Transcription FactorsMicroRNAsNeoplasm InvasivenessNeoplasm MetastasisOsteosarcomaReal-Time Polymerase Chain ReactionVascular Endothelial Growth Factor AKLF4 protein, humanKruppel-Like Factor 4Kruppel-Like Transcription FactorsMicroRNAsVascular Endothelial Growth Factor A

Identifiers

PMID29293555
PMCPMC5749745
OpenAlexW2738968909

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.